{
  "ticker": "ALXO",
  "company_name": "ALX Oncology Holdings Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT04417517",
      "title": "A Study of Evorpacept (ALX148) With Azacitidine for Higher Risk Myelodysplastic Syndrome (ASPEN-02)",
      "status": "TERMINATED",
      "phase": "PHASE1",
      "condition": "Higher Risk Myelodysplastic Syndromes",
      "start_date": "2020-10-02",
      "completion_date": "2025-06-10",
      "enrollment": 0,
      "sponsor": "ALX Oncology Inc."
    },
    {
      "nct_id": "NCT04675333",
      "title": "Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE2",
      "condition": "Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma",
      "start_date": "2021-05-10",
      "completion_date": "2026-06-30",
      "enrollment": 0,
      "sponsor": "ALX Oncology Inc."
    },
    {
      "nct_id": "NCT07007559",
      "title": "ASPEN-09: A Study of Evorpacept in Combination With Anti-cancer Therapies in Advanced / Metastatic Malignancies",
      "status": "RECRUITING",
      "phase": "PHASE1, PHASE2",
      "condition": "Breast Cancer, Metastatic",
      "start_date": "2025-04-28",
      "completion_date": "2027-12",
      "enrollment": 0,
      "sponsor": "ALX Oncology Inc."
    },
    {
      "nct_id": "NCT05167409",
      "title": "A Study of Evorpacept (ALX148) With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE2",
      "condition": "Microsatellite Stable Metastatic Colorectal Cancer",
      "start_date": "2022-07-28",
      "completion_date": "2026-03-01",
      "enrollment": 0,
      "sponsor": "University of Colorado, Denver"
    },
    {
      "nct_id": "NCT05524545",
      "title": "A Study of Evorpacept (ALX148) With Enfortumab Vedotin for Subjects With Urothelial Carcinoma (ASPEN-07)",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Bladder Cancer, Urothelial Carcinoma",
      "start_date": "2022-11-02",
      "completion_date": "2025-06-27",
      "enrollment": 0,
      "sponsor": "ALX Oncology Inc."
    },
    {
      "nct_id": "NCT04675294",
      "title": "Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE2",
      "condition": "Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma",
      "start_date": "2021-04-02",
      "completion_date": "2026-06-30",
      "enrollment": 0,
      "sponsor": "ALX Oncology Inc."
    },
    {
      "nct_id": "NCT07085091",
      "title": "A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors",
      "status": "RECRUITING",
      "phase": "PHASE1",
      "condition": "NSCLC (Advanced Non-small Cell Lung Cancer), HNSCC, CRC (Colorectal Cancer), ESCC, Colo-rectal Cancer, Head and Neck Cancer, Esophageal Squamous Cell Carcinoma (ESCC)",
      "start_date": "2025-08-18",
      "completion_date": "2027-12",
      "enrollment": 0,
      "sponsor": "ALX Oncology Inc."
    },
    {
      "nct_id": "NCT05027139",
      "title": "A Study of Zanidatamab (ZW25) With Evorpacept (ALX148) in Patients With Advanced HER2-expressing Cancer",
      "status": "COMPLETED",
      "phase": "PHASE1, PHASE2",
      "condition": "HER2-expressing Cancers",
      "start_date": "2021-09-15",
      "completion_date": "2025-09-30",
      "enrollment": 0,
      "sponsor": "Jazz Pharmaceuticals"
    },
    {
      "nct_id": "NCT05002127",
      "title": "A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE2, PHASE3",
      "condition": "Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma",
      "start_date": "2022-01-15",
      "completion_date": "2026-06",
      "enrollment": 0,
      "sponsor": "ALX Oncology Inc."
    },
    {
      "nct_id": "NCT05467670",
      "title": "Safety and Efficacy of Anti-CD47, ALX148 in Combination with Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer",
      "status": "RECRUITING",
      "phase": "PHASE2",
      "condition": "Ovarian Cancer",
      "start_date": "2023-03-30",
      "completion_date": "2031-12-31",
      "enrollment": 0,
      "sponsor": "Alexander B Olawaiye, MD"
    }
  ],
  "summary": {
    "total_trials": 12,
    "by_phase": {
      "PHASE1": 5,
      "PHASE2": 4,
      "PHASE1, PHASE2": 2,
      "PHASE2, PHASE3": 1
    },
    "by_status": {
      "TERMINATED": 2,
      "ACTIVE_NOT_RECRUITING": 4,
      "RECRUITING": 3,
      "COMPLETED": 3
    },
    "active_trials": 7,
    "completed_trials": 3,
    "conditions": [
      "Acute Myeloid Leukemia, AML, Adult",
      "Bladder Cancer, Urothelial Carcinoma",
      "Breast Cancer, Metastatic",
      "Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma",
      "HER2-expressing Cancers",
      "Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma",
      "Higher Risk Myelodysplastic Syndromes",
      "Metastatic Cancer, Solid Tumor, Advanced Cancer, NonHodgkin Lymphoma",
      "Microsatellite Stable Metastatic Colorectal Cancer",
      "NSCLC (Advanced Non-small Cell Lung Cancer), HNSCC, CRC (Colorectal Cancer), ESCC, Colo-rectal Cancer, Head and Neck Cancer, Esophageal Squamous Cell Carcinoma (ESCC)",
      "Ovarian Cancer"
    ],
    "lead_stage": "phase_2"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T14:00:09.094593",
    "search_query": "ALX Oncology Holdings Inc.",
    "url": "https://clinicaltrials.gov/search?term=ALX+Oncology+Holdings+Inc."
  }
}